Takeda Pharmaceutical Company Ltd
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.
Phase 3
Completed
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2009-12-16
- Last Posted Date
- 2012-02-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1071
- Registration Number
- NCT01033071
Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2013-03-26
- Lead Sponsor
- Takeda
- Target Recruit Count
- 784
- Registration Number
- NCT01023581
Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjects With Severe Hypertension
Phase 4
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2009-11-13
- Last Posted Date
- 2010-07-14
- Lead Sponsor
- Takeda
- Target Recruit Count
- 107
- Registration Number
- NCT01012479
Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma
Phase 3
Completed
- Conditions
- Adenocarcinoma, Prostate
- Interventions
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2015-07-30
- Lead Sponsor
- Takeda
- Target Recruit Count
- 311
- Registration Number
- NCT01011751
- Locations
- 🇫🇷
Professor Jacques IRANI, Poitiers, France
Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2009-11-03
- Last Posted Date
- 2016-04-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 426
- Registration Number
- NCT01007097
Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension
Phase 3
Completed
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2009-10-16
- Last Posted Date
- 2012-11-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 837
- Registration Number
- NCT00996281
Efficacy and Tolerability of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients Older Than 18 Years
- First Posted Date
- 2009-10-14
- Last Posted Date
- 2012-09-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 131
- Registration Number
- NCT00994760
- Locations
- 🇩🇪
Nycomed Deutschland GmbH, Zwönitz, Germany
Norwalk Vaccine Study
Phase 1
Completed
- Conditions
- Acute GastroenteritisNorwalk Virus Infection
- Interventions
- Biological: Norwalk VLP vaccineBiological: mannitol and sucroseBiological: Norwalk virus
- First Posted Date
- 2009-09-09
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 98
- Registration Number
- NCT00973284
- Locations
- 🇺🇸
Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸SNBL, Baltimore, Maryland, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Acute Coronary Syndrome
- Interventions
- Drug: PlaceboDrug: Alogliptin
- First Posted Date
- 2009-08-31
- Last Posted Date
- 2014-05-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 5380
- Registration Number
- NCT00968708
Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus
- First Posted Date
- 2009-08-12
- Last Posted Date
- 2015-01-29
- Lead Sponsor
- Takeda
- Target Recruit Count
- 46
- Registration Number
- NCT00957268
© Copyright 2025. All Rights Reserved by MedPath